Bhatia Sangeeta N. 4
4 · VERTEX PHARMACEUTICALS INC / MA · Filed May 3, 2023
Insider Transaction Report
Form 4
Bhatia Sangeeta N.
Director
Transactions
- Award
Common Stock
2023-05-01+1,168→ 5,208 total - Sale
Common Stock
2023-05-02$345.93/sh−62$21,448→ 5,146 total - Sale
Common Stock
2023-05-02$346.69/sh−172$59,631→ 4,974 total - Sale
Common Stock
2023-05-02$348.16/sh−120$41,779→ 4,854 total - Sale
Common Stock
2023-05-02$349.82/sh−163$57,021→ 4,691 total - Sale
Common Stock
2023-05-02$351.20/sh−63$22,126→ 4,628 total
Footnotes (8)
- [F1]Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.
- [F2]Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/17/2022.
- [F3]Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- [F4]Open market sales reported on this line occurred at a weighted average price of $345.93 (range $345.20 to $346.12).
- [F5]Open market sales reported on this line occurred at a weighted average price of $346.69 (range $346.31 to $347.03).
- [F6]Open market sales reported on this line occurred at a weighted average price of $348.16 (range $347.91 to $348.64).
- [F7]Open market sales reported on this line occurred at a weighted average price of $349.82 (range $349.17 to $350.08).
- [F8]Open market sales reported on this line occurred at a weighted average price of $351.20 (range $350.92 to $351.48).